Basilea reports significantly increased cash-generating revenue, flat operating expenses and reduced net loss for half-year 2019

Ads

You May Also Like

Repros Announces Initiation of Formal Approval Process by the European Medicines Agency

THE WOODLANDS, Texas, March 15, 2016 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today ...

XBiotech to Provide Third Quarter 2016 Business Update on November 15

AUSTIN, Texas, Nov. 10, 2016 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT), developer of True ...

FACIT and Triphase Accelerator Announce New Partnership with Celgene for First-in-class WDR5 Leukemia Therapy

Largest transaction to date for Canadian-discovered preclinical asset arises from Ontario collaboratorsTORONTO, ON, Jan. ...